[ET Net News Agency, 21 August 2026] Morgan Stanley raised the target price for Pharmaron (03759) to HKD35.6 from HKD31 and maintained the "overweight" rating.
The research house said it raises 2026-30 estimates by 1-6% to reflect higher revenue assumptions, management's upward-revised guidance and better working capital efficiency. (rc)
The research house said it raises 2026-30 estimates by 1-6% to reflect higher revenue assumptions, management's upward-revised guidance and better working capital efficiency. (rc)